Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis
To investigate how baseline clinical and molecular risk factors influence aggressive phenotypes in papillary thyroid microcarcinoma (PTMC).
Approach:
Systematic Review and Meta-Analysis: The study analyzed risk factors for lymph node metastasis (LNM) and extrathyroidal extension (ETE) using data from surgical cohorts of PTMC patients, calculating pooled odds ratios (OR) and 95% confidence intervals (CI).
Key Findings:
Increased odds of central lymph node metastasis (CLNM) associated with male sex (OR = 1.86; CI: 1.73–2.00), age (5 mm OR = 2.26; CI: 2.00–2.56), multifocality (OR = 1.96; CI: 1.78–2.16), bilaterality (OR = 1.70; CI: 1.45–2.00), and BRAFV600E mutation (OR = 1.51; CI: 1.25–1.82).
Lateral lymph node metastasis (LLNM) linked to male sex (OR = 1.69; CI: 1.51–1.90), age (5 mm OR = 2.34; CI: 1.68–3.25), multifocality (OR = 1.98; CI: 1.46–2.70), and bilaterality (OR = 1.91; CI: 1.22–3.00).
Extrathyroidal extension (ETE) risk factors include tumor size (>5 mm OR = 3.00; CI: 2.03–4.45), multifocality (OR = 2.41; CI: 1.99–2.91), bilaterality (OR = 2.58; CI: 1.26–5.27), and BRAFV600E mutation (OR = 2.19; CI: 1.61–2.97).
Interpretation:
Male sex, age (5 mm), multifocality, bilaterality, and BRAFV600E mutation are clinically relevant risk factors for aggressive PTMC phenotypes.
Conclusion:
The study establishes a clinicopathological baseline for individual patient profiles in PTMC.
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
